SpringWorks Therapeutics (SWTX)
(Delayed Data from NSDQ)
$45.53 USD
+1.33 (3.01%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $45.55 +0.02 (0.04%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth A Momentum F VGM
Fundamental Charts
About Cash from Investing (TTM)
The company's trailing twelve month (TTM) Cash from Investing is the sum of the company's past 12 months cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
SWTX 45.53 +1.33(3.01%)
Will SWTX be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for SWTX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for SWTX
Immunome (IMNM) to Acquire Desmoid Tumor Candidate, Stock Up
SpringWorks (SWTX) Surges More Than 80% in 3 Months: Here's Why
SWTX: What are Zacks experts saying now?
Zacks Private Portfolio Services
SpringWorks (SWTX) Rises on FDA Nod for Desmoid Tumor Drug
SpringWorks (SWTX) Falls Despite Positive Mirdametinib Study Data
Wall Street Analysts Think SpringWorks Therapeutics (SWTX) Could Surge 212%: Read This Before Placing a Bet
Other News for SWTX
SpringWorks Therapeutics: Newly Commercial Stage, Fully Valued Biotech Means Steer Clear
SpringWorks Therapeutics -- Newly Commercial Stage, Fully Valued Biotech Means Steer Clear
SpringWorks Therapeutics Announces Abstracts Accepted for Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
SpringWorks Therapeutics: Multiple Opportunities, But No Sure-Fire Winners
SpringWorks Therapeutics to Report First Quarter 2024 Financial Results Thursday, May 2, 2024